AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3103901 — intervention group
Group type: COMPARATOR
Intervention: Calcium pyrrolidone carboxylate
Number of subjects: 48
Study 28750549 — intervention group
Group type: EXPERIMENTAL
Intervention: Error augmentation
Number of subjects: 47
Study 28750549 — intervention group
Group type: EXPERIMENTAL
Intervention: Error minimization
Number of subjects: 47
Study 28750549 — intervention group
Group type: COMPARATOR
Intervention: Conventional treadmill training (control)
Number of subjects: 47
Study 27404642 — intervention group
Group type: EXPERIMENTAL
Intervention: Group meetings with 11 personal motivational calls
Number of subjects: 288
Study 27404642 — intervention group
Group type: EXPERIMENTAL
Intervention: Group meetings with 11 automated motivational messages
Number of subjects: 288
Study 27404642 — intervention group
Group type: COMPARATOR
Intervention: Group meetings with no calls
Number of subjects: 288
Study 23956009 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT) systems including optical frequency domain imaging (OFDI) and μOCT
Number of subjects: 0
Study 23956009 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT) systems
Number of subjects: 0
Study 21848863 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase 25,000 IU in both arterial and venous lines for each thrombotic event (Group A)
Number of subjects: 72
Study 21848863 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase 100,000 IU in both arterial and venous lines for each thrombotic event (Group B)
Number of subjects: 72
Study 20833862 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary falls prevention programme (including physiotherapy, occupational therapy, nurse, medical review, referral to specialists)
Number of subjects: 364
Study 20833862 — intervention group
Group type: COMPARATOR
Intervention: Falls prevention information leaflet
Number of subjects: 364
Study 18369669 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid Bond
Number of subjects: 50
Study 18369669 — intervention group
Group type: COMPARATOR
Intervention: Xeno III
Number of subjects: 50
Study 15626550 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training for 6 months
Number of subjects: 115
Study 15626550 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 115
Study 15626550 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 115
Study 12760507 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline fibres (TCF) applied in 5 pockets
Number of subjects: 10
Study 12760507 — intervention group
Group type: COMPARATOR
Intervention: Mechanical treatment only (scaling and root planing)
Number of subjects: 10
Study 12760507 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline fibres (TCF)
Number of subjects: 10
Study 11689389 — intervention group
Group type: EXPERIMENTAL
Intervention: Paricalcitol dosing based on baseline intact parathyroid hormone (iPTH; PTH/80) level
Number of subjects: 125
Study 11689389 — intervention group
Group type: EXPERIMENTAL
Intervention: Paricalcitol dosing based on patient body weight (0.04 microgram/kg)
Number of subjects: 125
Study 9393221 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy
Number of subjects: 5176
Study 9393221 — intervention group
Group type: COMPARATOR
Intervention: Dual therapy
Number of subjects: 5176
Study 9393221 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy
Number of subjects: 5176
Study 9393221 — intervention group
Group type: COMPARATOR
Intervention: Antiretroviral combination therapies (1991-1996)
Number of subjects: 5176
Study 8180867 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% of 150 ml of nonionic contrast agent (ivoversol, 320 mg/ml)
Number of subjects: 45
Study 8180867 — intervention group
Group type: COMPARATOR
Intervention: 75% of 150 ml of nonionic contrast agent (ivoversol, 320 mg/ml)
Number of subjects: 45
Study 8180867 — intervention group
Group type: EXPERIMENTAL
Intervention: 65% of 150 ml of nonionic contrast agent (ivoversol, 320 mg/ml)
Number of subjects: 45
Study 8180867 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% of 150 ml of nonionic contrast agent (ivoversol, 320 mg/ml)
Number of subjects: 45
Study 8180867 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% of 150 ml of nonionic contrast agent (ivoversol, 320 mg/ml)
Number of subjects: 45
Study 3286517 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg b.i.d. for UTI (22 cases)
Number of subjects: 92
Study 3286517 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 250 mg b.i.d. for UTI (20 cases)
Number of subjects: 92
Study 3286517 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg s.i.d. for UTI (20 cases)
Number of subjects: 92
Study 3286517 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg b.i.d. for RTI (10 cases)
Number of subjects: 92
Study 3286517 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 250 mg b.i.d. for RTI (20 cases)
Number of subjects: 92
Study 29747540 — intervention group
Group type: EXPERIMENTAL
Intervention: real a‐tDCS (stimulation, 1.5 mA for 30 minutes)
Number of subjects: 40
Study 29747540 — intervention group
Group type: COMPARATOR
Intervention: sham a‐tDCS
Number of subjects: 40
Study 26507180 — intervention group
Group type: EXPERIMENTAL
Intervention: Awake-regional anaesthesia
Number of subjects: 722
Study 26507180 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 722
Study 24722763 — intervention group
Group type: EXPERIMENTAL
Intervention: ASD group
Number of subjects: 2
Study 24722763 — intervention group
Group type: COMPARATOR
Intervention: TD group
Number of subjects: 2
Study 24418877 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 g daily whole bean soy consumption for 18 months
Number of subjects: 90
Study 24418877 — intervention group
Group type: COMPARATOR
Intervention: Control group (normo-cholesterolemic women)
Number of subjects: 90
Study 20453692 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 0
Study 20453692 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 0
Study 19083462 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 microg/d of vitamin K in the form of phylloquinone (K(1))
Number of subjects: 14
Study 19083462 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 14
Study 14768515 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane anesthesia (maintained with isoflurane up to 1.2% end-tidal concentration)
Number of subjects: 42
Study 14768515 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl-isoflurane anesthesia (infusion of fentanyl at 3 micrograms/kg/h and maintained with isoflurane up to 0.6% end-tidal concentration)
Number of subjects: 42
Study 14768515 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane anesthesia
Number of subjects: 42
Study 14768515 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl-isoflurane anesthesia
Number of subjects: 42
Study 11004367 — intervention group
Group type: EXPERIMENTAL
Intervention: Early feeding of low residue diets 6 hours postoperatively
Number of subjects: 139
Study 11004367 — intervention group
Group type: COMPARATOR
Intervention: Traditional dietary management of clear liquids with normal bowel sounds, and regular diet with passage of flatus
Number of subjects: 139
Study 11004367 — intervention group
Group type: COMPARATOR
Intervention: Late feeding group
Number of subjects: 139
Study 11004367 — intervention group
Group type: EXPERIMENTAL
Intervention: Early feeding group
Number of subjects: 139
Study 8676624 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg riluzole daily
Number of subjects: 959
Study 8676624 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg riluzole daily
Number of subjects: 959
Study 8676624 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg riluzole daily
Number of subjects: 959
Study 8676624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 959
Study 1351736 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.6 microgram kg‐1
Number of subjects: 30
Study 1351736 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 30
Study 30770426 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light therapy (BLT) (±10,000 lux)
Number of subjects: 83
Study 30770426 — intervention group
Group type: COMPARATOR
Intervention: Control light (±200 lux)
Number of subjects: 83
Study 28474556 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferritin levels up to about 80 ng/mL
Number of subjects: 1277
Study 28474556 — intervention group
Group type: EXPERIMENTAL
Intervention: %TS levels up to about 25%
Number of subjects: 1277
Study 28474556 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferritin levels up to about 100 ng/mL
Number of subjects: 1277
Study 28474556 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferritin levels over 100 ng/mL
Number of subjects: 1277
Study 28474556 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified normal ranges for ferritin from about 15 ng/mL up to about 80-100 ng/mL
Number of subjects: 1277
Study 28474556 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified normal ranges for %TS from about 15% up to about 25-55%
Number of subjects: 1277
Study 25738178 — intervention group
Group type: EXPERIMENTAL
Intervention: Epithelial connective tissue graft (group A)
Number of subjects: 30
Study 25738178 — intervention group
Group type: COMPARATOR
Intervention: Porcine collagen matrix (group B)
Number of subjects: 30
Study 23614539 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) - 1.0 g loading dose followed by another 1.0 g dose 3 hours later
Number of subjects: 98
Study 23614539 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline placebo (control group)
Number of subjects: 98
Study 21904221 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute normovolemic hemodilution (HG) - 1000 mL of blood drawn and replaced with HES 130/0.4 (6%, Voluven) colloid.
Number of subjects: 40
Study 21904221 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) - no blood drawn, hemodynamics stabilized using normal saline.
Number of subjects: 40
Study 20032798 — intervention group
Group type: EXPERIMENTAL
Intervention: Ospemifene 60 mg/day
Number of subjects: 826
Study 20032798 — intervention group
Group type: EXPERIMENTAL
Intervention: Ospemifene 30 mg/day
Number of subjects: 826
Study 20032798 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 826
Study 18372722 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine (SCOP)
Number of subjects: 0
Study 18372722 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine (SCOP) in combination with dextroamphetamine (DEX)
Number of subjects: 0
Study 15699539 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRP-2 (1 microg/kg/h)
Number of subjects: 7
Study 15699539 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 7
Study 12469755 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond Multi-Purpose Plus
Number of subjects: 0
Study 12469755 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime & Bond 2.1 Dual Cure
Number of subjects: 0
Study 12469755 — intervention group
Group type: COMPARATOR
Intervention: Prime & Bond 2.1
Number of subjects: 0
Study 12469755 — intervention group
Group type: COMPARATOR
Intervention: Amalgambond Plus
Number of subjects: 0
Study 9674468 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol (hydrophilic beta-blocker)
Number of subjects: 20
Study 9674468 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (lipophilic beta-blocker)
Number of subjects: 20
Study 9674468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 7831697 — intervention group
Group type: EXPERIMENTAL
Intervention: Department of Neurology
Number of subjects: 243
Study 7831697 — intervention group
Group type: COMPARATOR
Intervention: Department of Medicine
Number of subjects: 243
Study 2194380 — intervention group
Group type: COMPARATOR
Intervention: Monovalent CR influenza virus vaccine (type A H3N2, H1N1 and type B)
Number of subjects: 57
Study 2194380 — intervention group
Group type: COMPARATOR
Intervention: Bivalent CR influenza virus vaccine (type A H3N2 and H1N1)
Number of subjects: 57
Study 2194380 — intervention group
Group type: COMPARATOR
Intervention: CR influenza virus vaccine
Number of subjects: 57
Study 382156 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous domperidone (20 mg initially, followed by maintenance doses of 10 mg at 6 hourly intervals)
Number of subjects: 106
Study 382156 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 31709895 — intervention group
Group type: EXPERIMENTAL
Intervention: Tunneled peripherally inserted central catheter
Number of subjects: 174
Study 31709895 — intervention group
Group type: COMPARATOR
Intervention: Nontunneled peripherally inserted central catheter
Number of subjects: 174
Study 31475465 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil solution applied every 12 hours for 30 days
Number of subjects: 571
Study 31475465 — intervention group
Group type: COMPARATOR
Intervention: Hyperoxygenated fatty acid compound applied every 12 hours for 30 days
Number of subjects: 571
Study 29254111 — intervention group
Group type: EXPERIMENTAL
Intervention: FES therapy plus conventional rehabilitation program
Number of subjects: 16
Study 29254111 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation program
Number of subjects: 16
Study 28162292 — intervention group
Group type: EXPERIMENTAL
Intervention: RRx-001 16.5mg/m2 IV 1x/week
Number of subjects: 26
Study 28162292 — intervention group
Group type: COMPARATOR
Intervention: Regorafenib 160mg orally 21 of 28 days
Number of subjects: 26
Study 28162292 — intervention group
Group type: EXPERIMENTAL
Intervention: RRx-001 + irinotecan
Number of subjects: 26
Study 28162292 — intervention group
Group type: COMPARATOR
Intervention: Regorafenib + irinotecan
Number of subjects: 26
Study 23392087 — intervention group
Group type: COMPARATOR
Intervention: Oral hygiene instructions (OHI) annually (Control group)
Number of subjects: 266
Study 23392087 — intervention group
Group type: EXPERIMENTAL
Intervention: OHI and silver diamine fluoride (SDF) application annually
Number of subjects: 266
Study 23392087 — intervention group
Group type: EXPERIMENTAL
Intervention: OHI and SDF application annually, plus oral health education (OHE) programme every 6 months
Number of subjects: 266
Study 21816957 — intervention group
Group type: EXPERIMENTAL
Intervention: eCancerCare(Bladder)
Number of subjects: 12
Study 21816957 — intervention group
Group type: COMPARATOR
Intervention: EMR
Number of subjects: 12
Study 19139161 — intervention group
Group type: EXPERIMENTAL
Intervention: Fairness with intergroup competition present
Number of subjects: 0
Study 19139161 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrimination without intergroup competition
Number of subjects: 0
Study 19139161 — intervention group
Group type: EXPERIMENTAL
Intervention: Fairness without intergroup competition
Number of subjects: 0
Study 19139161 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrimination with intergroup competition
Number of subjects: 0
Study 16868693 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass mailing recruitment strategy
Number of subjects: 0
Study 15101070 — intervention group
Group type: EXPERIMENTAL
Intervention: Crisis intervention model (additional therapy visits if needed)
Number of subjects: 30
Study 15101070 — intervention group
Group type: COMPARATOR
Intervention: Follow-up only (no additional therapy visits)
Number of subjects: 30
Study 11746070 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-mentored HIV risk-reduction program
Number of subjects: 633
Study 11746070 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse case-managed HIV risk-reduction program
Number of subjects: 633
Study 11746070 — intervention group
Group type: COMPARATOR
Intervention: Standard care HIV risk-reduction program
Number of subjects: 633
Study 9014950 — intervention group
Group type: COMPARATOR
Intervention: Single task performance (CVA groups)
Number of subjects: 36
Study 9014950 — intervention group
Group type: COMPARATOR
Intervention: Combined computer tasks (CVA groups)
Number of subjects: 36
Study 9014950 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual attentional task (Right CVA group)
Number of subjects: 36
Study 9014950 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual attentional task (Stroke subjects driving)
Number of subjects: 36
Study 8323310 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultured epidermal allografts
Number of subjects: 9
Study 8323310 — intervention group
Group type: COMPARATOR
Intervention: Nonadherent dressings
Number of subjects: 9
Study 3553495 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker (oxprenolol)
Number of subjects: 60
Study 3553495 — intervention group
Group type: COMPARATOR
Intervention: Calcium-entry blocker (nitrendipine)
Number of subjects: 60
Study 29930257 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep-learned 3D black-blood imaging
Number of subjects: 65
Study 29930257 — intervention group
Group type: COMPARATOR
Intervention: Original black-blood imaging
Number of subjects: 65
Study 28417279 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacker
Number of subjects: 66
Study 28417279 — intervention group
Group type: COMPARATOR
Intervention: Cyanoacrylate glue mesh fixation
Number of subjects: 66
Study 26250761 — intervention group
Group type: EXPERIMENTAL
Intervention: DHS questionnaire
Number of subjects: 1189
Study 26250761 — intervention group
Group type: COMPARATOR
Intervention: SSC questionnaire
Number of subjects: 1189
Study 23414298 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of calcipotriol ointment twice daily (group I)
Number of subjects: 40
Study 23414298 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of calcipotriol ointment twice daily and NB‐UVB phototherapy once a week (group II)
Number of subjects: 40
Study 23414298 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of heparinoid ointment twice daily and NB‐UVB phototherapy more than twice a week (group III)
Number of subjects: 40
Study 23414298 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of calcipotriol ointment twice daily and NB‐UVB phototherapy more than twice a week (group IV)
Number of subjects: 40
Study 23414298 — intervention group
Group type: COMPARATOR
Intervention: All treatment groups
Number of subjects: 40
Study 21347647 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (T) for 5 years
Number of subjects: 504
Study 21347647 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (CT)
Number of subjects: 504
Study 21347647 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus Tamoxifen (CTT)
Number of subjects: 504
Study 21347647 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (T)
Number of subjects: 504
Study 19092335 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane preconditioning
Number of subjects: 64
Study 19092335 — intervention group
Group type: COMPARATOR
Intervention: Control (no sevoflurane preconditioning)
Number of subjects: 64
Study 17015900 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced full-dose PET/CT
Number of subjects: 47
Study 17015900 — intervention group
Group type: COMPARATOR
Intervention: Unenhanced low-dose PET/CT
Number of subjects: 47
Study 17015900 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PET/CT modalities
Number of subjects: 47
Study 12643320 — intervention group
Group type: EXPERIMENTAL
Intervention: Danaparoid (10 IU/kg) administered subcutaneously twice daily for a mean of 16 days.
Number of subjects: 45
Study 12643320 — intervention group
Group type: EXPERIMENTAL
Intervention: Danaparoid (2.6 IU/kg/h) administered intravenously for a mean of 17 days.
Number of subjects: 45
Study 10836653 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab
Number of subjects: 535
Study 10836653 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 535
Study 9115027 — intervention group
Group type: EXPERIMENTAL
Intervention: Misclassified male ever-smokers in cohort I
Number of subjects: 0
Study 9115027 — intervention group
Group type: EXPERIMENTAL
Intervention: Misclassified female ever-smokers in cohort I
Number of subjects: 0
Study 9115027 — intervention group
Group type: EXPERIMENTAL
Intervention: Former smokers in cohort I
Number of subjects: 0
Study 9115027 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers in cohort I
Number of subjects: 0
Study 9115027 — intervention group
Group type: COMPARATOR
Intervention: Misclassified never-smokers in cohort I
Number of subjects: 0
Study 9115027 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort II results
Number of subjects: 0
Study 8250362 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous blood transfusion (n = 13)
Number of subjects: 35
Study 8250362 — intervention group
Group type: EXPERIMENTAL
Intervention: Homologous blood transfusion (n = 10)
Number of subjects: 35
Study 8250362 — intervention group
Group type: COMPARATOR
Intervention: Control group (no transfusion, n = 12)
Number of subjects: 35
Study 2944136 — intervention group
Group type: EXPERIMENTAL
Intervention: Inversion traction for two minutes
Number of subjects: 60
Study 2944136 — intervention group
Group type: COMPARATOR
Intervention: Control Group (standing for two minutes)
Number of subjects: 60
Study 30362518 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy plus enoxaparin (40 mg daily)
Number of subjects: 0
Study 30362518 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiotherapy only
Number of subjects: 0
Study 28619985 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm-and-music therapy
Number of subjects: 123
Study 28619985 — intervention group
Group type: EXPERIMENTAL
Intervention: Horse-riding therapy
Number of subjects: 123
Study 28619985 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 123
Study 28619985 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm-and-music therapy and Horse-riding therapy
Number of subjects: 123
Study 25863524 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity, low volume aerobic exercise (HI:LO, 70% VO2peak, 45 min, 3d/week)
Number of subjects: 48
Study 25863524 — intervention group
Group type: EXPERIMENTAL
Intervention: Low to moderate intensity, high volume aerobic exercise (LO:HI, 50% VO2peak, 60 min, 4d/week)
Number of subjects: 48
Study 25863524 — intervention group
Group type: EXPERIMENTAL
Intervention: Low to moderate intensity, low volume aerobic exercise (LO:LO, 50% VO2peak, 45 min, 3d/week)
Number of subjects: 48
Study 25863524 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 48